vs
Side-by-side financial comparison of Abbott Laboratories (ABT) and Accenture (ACN). Click either name above to swap in a different company.
Accenture is the larger business by last-quarter revenue ($18.0B vs $11.5B, roughly 1.6× Abbott Laboratories). Abbott Laboratories runs the higher net margin — 15.5% vs 10.1%, a 5.4% gap on every dollar of revenue. On growth, Accenture posted the faster year-over-year revenue change (8.3% vs 4.4%). Accenture produced more free cash flow last quarter ($3.7B vs $2.6B). Over the past eight quarters, Abbott Laboratories's revenue compounded faster (7.2% CAGR vs 4.7%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Accenture plc is a Irish technology consulting company headquartered in Dublin, Ireland. Founded in 1989, Accenture provides information technology and management consulting services across 120 countries globally.
ABT vs ACN — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $11.5B | $18.0B |
| Net Profit | $1.8B | $1.8B |
| Gross Margin | 57.0% | 30.3% |
| Operating Margin | 19.6% | 13.8% |
| Net Margin | 15.5% | 10.1% |
| Revenue YoY | 4.4% | 8.3% |
| Net Profit YoY | -80.8% | 2.1% |
| EPS (diluted) | $1.01 | $2.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.0B | ||
| Q4 25 | $11.5B | $18.7B | ||
| Q3 25 | $11.4B | $17.6B | ||
| Q2 25 | $11.1B | $17.7B | ||
| Q1 25 | $10.4B | $16.7B | ||
| Q4 24 | $11.0B | $17.7B | ||
| Q3 24 | $10.6B | $16.4B | ||
| Q2 24 | $10.4B | $16.5B |
| Q1 26 | — | $1.8B | ||
| Q4 25 | $1.8B | $2.2B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.8B | $2.2B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $9.2B | $2.3B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | $1.3B | $1.9B |
| Q1 26 | — | 30.3% | ||
| Q4 25 | 57.0% | 33.1% | ||
| Q3 25 | 55.4% | 31.9% | ||
| Q2 25 | 56.4% | 32.9% | ||
| Q1 25 | 56.9% | 29.9% | ||
| Q4 24 | 55.0% | 32.9% | ||
| Q3 24 | 55.8% | 32.5% | ||
| Q2 24 | 55.6% | 33.4% |
| Q1 26 | — | 13.8% | ||
| Q4 25 | 19.6% | 15.3% | ||
| Q3 25 | 18.1% | 11.6% | ||
| Q2 25 | 18.4% | 16.8% | ||
| Q1 25 | 16.3% | 13.5% | ||
| Q4 24 | 17.4% | 16.7% | ||
| Q3 24 | 17.5% | 14.3% | ||
| Q2 24 | 16.1% | 16.0% |
| Q1 26 | — | 10.1% | ||
| Q4 25 | 15.5% | 11.8% | ||
| Q3 25 | 14.5% | 8.0% | ||
| Q2 25 | 16.0% | 12.4% | ||
| Q1 25 | 12.8% | 10.7% | ||
| Q4 24 | 84.1% | 12.9% | ||
| Q3 24 | 15.5% | 10.3% | ||
| Q2 24 | 12.5% | 11.7% |
| Q1 26 | — | $2.93 | ||
| Q4 25 | $1.01 | $3.54 | ||
| Q3 25 | $0.94 | $2.25 | ||
| Q2 25 | $1.01 | $3.49 | ||
| Q1 25 | $0.76 | $2.82 | ||
| Q4 24 | $5.26 | $3.59 | ||
| Q3 24 | $0.94 | $2.67 | ||
| Q2 24 | $0.74 | $3.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9B | $9.4B |
| Total DebtLower is stronger | $12.9B | $5.0B |
| Stockholders' EquityBook value | $52.1B | $31.2B |
| Total Assets | $86.7B | $67.1B |
| Debt / EquityLower = less leverage | 0.25× | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.4B | ||
| Q4 25 | $8.9B | $9.7B | ||
| Q3 25 | $7.7B | $11.5B | ||
| Q2 25 | $7.3B | $9.6B | ||
| Q1 25 | $6.8B | $8.5B | ||
| Q4 24 | $8.0B | $8.3B | ||
| Q3 24 | $7.8B | $5.0B | ||
| Q2 24 | $7.2B | $5.5B |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $12.9B | $5.0B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $5.0B | ||
| Q4 24 | $14.1B | $5.0B | ||
| Q3 24 | — | $78.6M | ||
| Q2 24 | — | $68.9M |
| Q1 26 | — | $31.2B | ||
| Q4 25 | $52.1B | $30.9B | ||
| Q3 25 | $51.0B | $31.2B | ||
| Q2 25 | $50.6B | $30.6B | ||
| Q1 25 | $48.8B | $29.2B | ||
| Q4 24 | $47.7B | $29.2B | ||
| Q3 24 | $39.8B | $28.3B | ||
| Q2 24 | $39.3B | $27.7B |
| Q1 26 | — | $67.1B | ||
| Q4 25 | $86.7B | $64.7B | ||
| Q3 25 | $84.2B | $65.4B | ||
| Q2 25 | $84.0B | $63.4B | ||
| Q1 25 | $81.4B | $59.9B | ||
| Q4 24 | $81.4B | $59.9B | ||
| Q3 24 | $74.4B | $55.9B | ||
| Q2 24 | $73.0B | $54.1B |
| Q1 26 | — | 0.16× | ||
| Q4 25 | 0.25× | 0.16× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.16× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | 0.30× | 0.17× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $3.8B |
| Free Cash FlowOCF − Capex | $2.6B | $3.7B |
| FCF MarginFCF / Revenue | 22.9% | 20.3% |
| Capex IntensityCapex / Revenue | 6.0% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.87× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $7.4B | $12.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.8B | ||
| Q4 25 | $3.3B | $1.7B | ||
| Q3 25 | $2.8B | $3.9B | ||
| Q2 25 | $2.0B | $3.7B | ||
| Q1 25 | $1.4B | $2.9B | ||
| Q4 24 | $2.9B | $1.0B | ||
| Q3 24 | $2.7B | $3.4B | ||
| Q2 24 | $2.0B | $3.1B |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $2.6B | $1.5B | ||
| Q3 25 | $2.3B | $3.8B | ||
| Q2 25 | $1.5B | $3.5B | ||
| Q1 25 | $933.0M | $2.7B | ||
| Q4 24 | $2.1B | $870.3M | ||
| Q3 24 | $2.1B | $3.2B | ||
| Q2 24 | $1.4B | $3.0B |
| Q1 26 | — | 20.3% | ||
| Q4 25 | 22.9% | 8.0% | ||
| Q3 25 | 20.2% | 21.6% | ||
| Q2 25 | 13.9% | 19.8% | ||
| Q1 25 | 9.0% | 16.1% | ||
| Q4 24 | 19.6% | 4.9% | ||
| Q3 24 | 20.2% | 19.4% | ||
| Q2 24 | 13.8% | 18.3% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 6.0% | 0.8% | ||
| Q3 25 | 4.4% | 0.6% | ||
| Q2 25 | 4.5% | 1.0% | ||
| Q1 25 | 4.7% | 1.0% | ||
| Q4 24 | 6.6% | 0.9% | ||
| Q3 24 | 5.2% | 1.3% | ||
| Q2 24 | 5.1% | 0.8% |
| Q1 26 | — | 2.09× | ||
| Q4 25 | 1.87× | 0.75× | ||
| Q3 25 | 1.70× | 2.77× | ||
| Q2 25 | 1.15× | 1.68× | ||
| Q1 25 | 1.07× | 1.60× | ||
| Q4 24 | 0.31× | 0.45× | ||
| Q3 24 | 1.64× | 2.01× | ||
| Q2 24 | 1.51× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABT
Segment breakdown not available.
ACN
| Products | $5.5B | 30% |
| Health And Public Service | $3.7B | 20% |
| Financial Services Sector | $3.4B | 19% |
| Communications Media And Technology | $3.1B | 17% |
| Resources | $2.4B | 13% |
